Sonoma Pharmaceuticals registers HOCl facial spray under U.S. cosmetics law

* Sonoma Pharmaceuticals (NASDAQ:SNOA [https://seekingalpha.com/symbol/SNOA]) has registered its Microcyn-based facial spray and manufacturing facility under the FDA’s Modernization of Cosmetics Regulation Act of 2022.
* The registration allows Sonoma to commercialize HOCl-based products as cosmetics in the U.S., expanding its regulatory footprint.
* Sonoma’s facility was already FDA-registered for medical device manufacturing, supporting a broad portfolio in wound care, dermatology, eye care, podiatry, and animal health.
* The MoCRA listing positions Sonoma to enter the fast-growing U.S. skincare market, projected to reach $40B by 2030.
* The company highlights its patented hypochlorous acid technology as a clean, effective solution for common skin conditions, aligning with rising demand for science-backed skincare.
* SNOA shares down 5.5% premarket on Tuesday.
* Source: Press release [https://seekingalpha.com/pr/20257004-sonoma-pharmaceuticals-expands-market-reach-with-fda-cosmetic-product-facility-registration]

MORE ON SONOMA PHARMACEUTICALS

* Seeking Alpha’s Quant Rating on Sonoma Pharmaceuticals [https://seekingalpha.com/symbol/SNOA/ratings/quant-ratings]
* Historical earnings data for Sonoma Pharmaceuticals [https://seekingalpha.com/symbol/SNOA/earnings]
* Financial information for Sonoma Pharmaceuticals [https://seekingalpha.com/symbol/SNOA/income-statement]